"The U.S. Food and Drug Administration today approved Clinolipid (lipid injectable emulsion, USP) for intravenous feeding (parenteral nutrition) in adult patients, providing a source of calories and essential fatty acids for adult patients who are"...
- The majority of adverse reactions to CroFab (crotalidae polyvalent immune fab ovine) reported in clinical studies were mild or moderate in severity.
- The most common adverse events reported in the clinical studies were urticaria and rash. Adverse events involving the skin and appendages (primarily rash, urticaria, and pruritus) were reported in 14 of the 42 patients (Table 6).
- Of the 25 patients who experienced adverse reactions, 3 patients experienced severe or serious adverse reactions. The 1 patient who experienced a serious adverse event had a recurrent coagulopathy due to envenomation, which required re-hospitalization and additional antivenin administration. This patient eventually made a complete recovery. The other 2 had severe adverse reactions that consisted of 1 patient who developed severe hives following treatment and 1 patient who developed a severe rash and pruritus several days following treatment. Both patients recovered following treatment with antihistamines and prednisone.
- One patient discontinued CroFab (crotalidae polyvalent immune fab ovine) therapy due to an allergic reaction.
Table 6. Incidence of Clinical Adverse Events in Studies
of CroFab (crotalidae polyvalent immune fab ovine) by Body System
Number of Events
|Body as a Whole|
|Skin and Appendages|
|*Of the 42 patients receiving CroFab (crotalidae polyvalent immune fab ovine) in the clinical studies,
25 experienced an adverse event. A total of 40 adverse events was experienced
by these 25 patients.
†Allergic reaction consisted of urticaria, dyspnea and wheezing in 1 patient.
In the 42 patients treated with CroFab (crotalidae polyvalent immune fab ovine) for minimal or moderate crotalid envenomations, there were 7 events classified as early serum reactions and 5 events classified as late serum reactions, and none were serious (Table 7). In the clinical studies, serum reactions consisted mainly of urticaria and rash, and all patients recovered without sequelae.
Table 7. Incidence of Early and Late Serum Reactions (Reactions
Associated with CroFab (crotalidae polyvalent immune fab ovine) Infusion)
Number of Events
|Early Serum Reactions|
|Late Serum Reactions|
|*6 of 42 patients experienced an adverse event associated
with an early serum reaction and 4 experienced an adverse event associated
with a late serum reaction. Two additional patients were considered to have
a late serum reaction by the investigator, although no associated adverse
event was reported.
**Allergic reaction consisted of urticaria, dyspnea and wheezing in 1 patient.
†Serum sickness consisted of severe rash and pruritus in 1 patient.
Read the Crofab (crotalidae polyvalent immune fab ovine) Side Effects Center for a complete guide to possible side effects
Studies of drug interactions have not been conducted with CroFab (crotalidae polyvalent immune fab ovine) .
Last reviewed on RxList: 9/11/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Crofab Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.